STSA
Closed
Satsuma Pharmaceuticals Inc
1.1
0.0 (0.00%)
Last Update: 09 Jun 2023 16:30:00
Yesterday: 1.11
Day's Range: 1.1 - 1.1
Send
sign up or login to leave a comment!
When Written:
0.7171
Satsuma Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that was founded in 2016 and is headquartered in South San Francisco, California. The company is focused on developing and commercializing novel therapies for the acute treatment of migraine and other neurological disorders.
Satsuma's lead product candidate is STS101, a drug-device combination product that is being developed for the acute treatment of migraine. STS101 is a dry-powder nasal spray that contains dihydroergotamine mesylate (DHE), a potent vasoconstrictor that has been used for the treatment of migraine for over 70 years. The company believes that STS101 has the potential to provide rapid and sustained relief from migraine pain, with fewer side effects than existing treatments.
Satsuma completed a Phase 3 clinical trial of STS101 in 2020, which demonstrated statistically significant improvements in pain relief and other migraine-related symptoms compared to placebo. The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2021.
Satsuma is also exploring the potential of STS101 for the treatment of other neurological disorders, such as cluster headache and post-traumatic headache. The company has a strong intellectual property portfolio, with multiple patents covering STS101 and related technologies.
Satsuma is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol "STSA".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Satsuma's lead product candidate is STS101, a drug-device combination product that is being developed for the acute treatment of migraine. STS101 is a dry-powder nasal spray that contains dihydroergotamine mesylate (DHE), a potent vasoconstrictor that has been used for the treatment of migraine for over 70 years. The company believes that STS101 has the potential to provide rapid and sustained relief from migraine pain, with fewer side effects than existing treatments.
Satsuma completed a Phase 3 clinical trial of STS101 in 2020, which demonstrated statistically significant improvements in pain relief and other migraine-related symptoms compared to placebo. The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2021.
Satsuma is also exploring the potential of STS101 for the treatment of other neurological disorders, such as cluster headache and post-traumatic headache. The company has a strong intellectual property portfolio, with multiple patents covering STS101 and related technologies.
Satsuma is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol "STSA".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!